

May 18, 2022

## WuXi Biologics (Cayman) Inc.

Level 54, Hopewell Centre 183 Queen's Road East Hong Kong

Attention: The Board of Directors

Dear Sirs,

WuXi Biologics (Cayman) Inc. (the "Company", together with its subsidiaries, the "Group") Connected transaction involving grants of restricted shares to connected persons pursuant to specific mandate

We refer to the circular of the Company dated May 18, 2022 in connection with the captioned matter (the "Circular"). Capitalised terms used herein shall have the same meanings as defined in the Circular unless otherwise stated.

We hereby give and have not withdrawn our consent to the issue of the Circular with the inclusion therein of our letter of advice and references to our name in the form and context in which it appears in the Circular.

We further confirm that, as at the Latest Practicable Date, we did not:

- (a) have any shareholding in any member of the Group or the right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of the Group, and
- (b) have any direct or indirect interest in any assets which had, since December 31, 2021 (being the date to which the latest published consolidated financial statements of the Company were made up), been acquired or disposed of by, or leased to any member of the Group, or are proposed to be acquired or disposed of by, or leased to any member of the Group.

We further consent to our letter of advice and this letter to be made available by the Company for public inspection in the manner set out in the section headed "10. DOCUMENTS AVAILABLE FOR DISPLAY AND INSPECTION" under Appendix I to the Circular.

Yours faithfully,

For and on behalf of

**Opus Capital Limited** 

Namer Andrew Cheung